Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07281833 | Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment(CAPIcorn) | recruiting | Phase 3 | 250 | Women's Cancer Study Group GmbHOTHER | 3 | Aug 5, 2026 | clinicaltrials |
| NCT07580105 | Clinical Study to Assess the Safety and Performance of Kenko Breast AI+ Medical Device as an Aid to Breast Cancer Diagnosis in Adult Women | recruiting | — | 200 | Kenko Imalytics S.L. |
| 1 |
| Aug 5, 2026 |
| clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT05621564 | Pre-operative Therapy in Breast Cancer | recruiting | — | 6,032 | RenJi HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06123286 | Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms | recruiting | Early Phase 1 | 30 | Philip ChangOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06195306 | Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06748222 | E-Mindfulness Approaches for Living After Breast Cancer(HEAL-ABC) | recruiting | Phase 3 | 402 | NRG OncologyOTHER | 2 | Aug 4, 2026 | clinicaltrials |
| NCT07017673 | Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | recruiting | Phase 2 | 34 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07078604 | A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 | 20 | University of WashingtonOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07739485 | Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study(GBCF003) | recruiting | Phase 1 / Phase 2 | 30 | Liu ShuOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07743827 | Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors | recruiting | N/A | 90 | Alexandria UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07743944 | A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.(VERITAS) | recruiting | — | 2,000 | AstraZenecaINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04360330 | SABER Study for Selected Early Stage Breast Cancer(SABER) | recruiting | N/A | 18 | University of MiamiOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06081244 | NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)(ADAPT-TN-III) | recruiting | Phase 3 | 348 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06922708 | Implementing Polygenic Risk Scores for Breast Cancer Prevention: a Feasibility Study(MIG) | recruiting | N/A | 100 | Catholic University of the Sacred HeartOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07225309 | A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer | recruiting | N/A | 300 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Aug 3, 2026 | clinicaltrials |
| NCT07673588 | Instagram and Podcast Intervention for Breast Cancer Awareness and Screening | recruiting | N/A | 180 | Ankara UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04521764 | A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer | recruiting | Phase 1 | 54 | Mayo ClinicOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05372640 | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05625659 | Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts(CMIST) | recruiting | N/A | 2,032 | American College of RadiologyOTHER | 2 | Jul 31, 2026 | clinicaltrials |
| NCT06954337 | MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial | recruiting | N/A | 1,750 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07295457 | Clinical Trial Evaluating the Efficacy and Implementation of an Early Adapted Physical Activity to Prevent and Manage Aromatase Inhibitor-induced Musculoskeletal Pain in Breast Cancer (APIS)(APIS) | recruiting | N/A | 182 | Hospices Civils de LyonOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07646847 | A Study of a Side Effects and Resource Navigation Program for People With Cancer | recruiting | N/A | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07738770 | Analgesic Efficacy of Combined PECS II and PIP Block Versus Thoracic Paravertebral Block Post-Mastectomy(PECS-TPVB) | recruiting | N/A | 72 | Dharmais National Cancer Center HospitalOTHER_GOV | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06113016 | Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors(PROFFi) | recruiting | Phase 2 | 164 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06486883 | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype(PONTIAC) | recruiting | Phase 2 | 200 | MedSIROTHER | 10 | Jul 30, 2026 | clinicaltrials |
| NCT06959537 | A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | recruiting | Phase 1 | 162 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 29, 2026 | clinicaltrials |
| NCT06802172 | Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial | recruiting | N/A | 100 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07229417 | A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma | recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732491 | Culmerciclib in HR+/HER2+ Advanced Breast Cancer | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07734389 | Genetic Assessment of Breast Cancer Risk in Women in the DORA Programme | recruiting | N/A | 291 | Institute of Oncology LjubljanaOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06121453 | Adherence Intervention in Patients With Metastatic Breast Cancer | recruiting | N/A | 35 | Columbia UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06347068 | Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | recruiting | Phase 1 | 42 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07731477 | The Effect of a Virtual Reality-Based Mindfulness Intervention on Anxiety, Comfort, Sleep, and Fatigue in Breast Cancer Patients Undergoing Chemotherapy | recruiting | N/A | 50 | Hacettepe UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02476786 | Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | recruiting | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06184750 | Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial | recruiting | Phase 2 | 200 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06369285 | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer(ALISCA-Breast1) | recruiting | Phase 2 | 225 | Puma Biotechnology, Inc.INDUSTRY | 3 | Jul 27, 2026 | clinicaltrials |
| NCT07729423 | Mepitel Film Breast | recruiting | — | 60 | National University Hospital, SingaporeOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06078384 | Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC(ETNA) | recruiting | Phase 2 | 354 | UNICANCEROTHER | 2 | Jul 24, 2026 | clinicaltrials |
| NCT06026657 | Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 42 | Margaret Gatti-MaysOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06225505 | Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)(CUPCAKE) | recruiting | N/A | 450 | Institut CurieOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06471205 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06545942 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 220 | MOMA TherapeuticsINDUSTRY | 3 | Jul 23, 2026 | clinicaltrials |
| NCT06606730 | Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer(OPT-PEMBRO) | recruiting | Phase 3 | 2,454 | UNICANCEROTHER | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07042243 | The Florida ASCENT Study | recruiting | N/A | 100 | University of FloridaOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07120087 | Evaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk.(MyPREV) | recruiting | N/A | 1,508 | UNICANCEROTHER | 2 | Jul 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2026source: clinicaltrials